A PHASE II TRIAL OF Hu3S193 THERAPY FOR PATIENTS WITH PLATINUM REFRACTORY OR PLATINUM RESISTANT EPITHELIAL OVARIAN, PRIMARY PERITONEAL AND FALLOPIAN TUBE CANCER.
Phase of Trial: Phase II
Latest Information Update: 27 May 2015
At a glance
- Drugs Monoclonal antibody 3S193 (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 15 Jun 2012 Actual patient number is 31 according to ClinicalTrials.gov.
- 15 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.